Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Armando Santoro(IRCCS Humanitas Research Hospital), Lorenza Rimassa(IRCCS Humanitas Research Hospital), Ivan Borbath(Cliniques Universitaires Saint-Luc), Bruno Daniele(Azienda Ospedaliera G.Rummo), Stefania Salvagni(Ospedale di Parma), Jean‐Luc Van Laethem(Erasmus Hospital), Hans Van Vlierberghe(Ghent University Hospital), Jörg Trojan(Goethe University Frankfurt), Frank T. Kolligs, Alan Weiss(Vancouver General Hospital), Steven A. Miles(Cedars-Sinai Medical Center), Antonio Gasbarrini(Agostino Gemelli University Polyclinic), Monica Lencioni(Azienda Ospedaliera Universitaria Pisana), Luca Cicalese, Morris Sherman(Toronto General Hospital), Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Peter Buggisch(Asklepios Klinik St. Georg), Guido Gerken(Essen University Hospital), Roland M. Schmid(Klinikum rechts der Isar), C. Boni, Nicola Personeni(IRCCS Humanitas Research Hospital), Ziad Hassoun(Cliniques Universitaires Saint-Luc), Giovanni Abbadessa(Arqule (United States)), Brian Schwartz(Arqule (United States)), Reinhard von Roemeling(Daiichi Sankyo (United States)), Maria Lamar(Arqule (United States)), Yinpu Chen(Arqule (United States)), Camillo Porta(Policlinico San Matteo Fondazione)
Cited by 550
Abstract
Related Papers
No related papers found
Powered by citation graph analysis